FDA
-
-
-
-
-
-
-
FDA approves Sanofi's Cablivi for pediatric blood clotting disorder
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
-
-
-
-
-
-
-
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
-
-
-
-
-
-
-
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
-
-
-
-
-
-
-
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
-
-
-
-
-
-
-
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
-
322,850 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

